The deeply discounted offering and massive warrant overhang signal severe capital needs and likely further price deterioration. Existing shareholders face extreme dilution. Monitor for shareholder vote on warrant approval by July 21, 2026 — if approved, the overhang becomes exercisable, adding further selling pressure. The stock is likely to trade down toward the offering price of $0.325 or below.
Price Chart
Executive Summary
AIM ImmunoTech entered into a securities purchase agreement and placement agency agreement for a combined registered direct offering and private placement, selling 7,519,351 shares of common stock at $0.325 per share (a ~21% discount to the prior close of $0.41) to institutional investors, along with Series I warrants to purchase up to 15,038,702 additional shares at $0.325 per share (subject to shareholder approval). The offering raised approximately $2.44M in gross proceeds, with net proceeds of ~$2.25M for working capital. This follows a 424B5 filed just one day prior for the same offering, and a prior 424B5 on May 19 suspending an ATM facility. The massive potential dilution (up to ~22.6M new shares vs. a ~$2M market cap) and deeply discounted pricing are strongly bearish for existing common shareholders.
Key Financial Metrics
Key Facts
- Company sold 7,519,351 shares at $0.325/share, a ~21% discount to the $0.41 closing price on May 18, 2026.
- Gross proceeds of ~$2.44M; net proceeds of ~$2.25M after placement agent fees and expenses.
- Issued Series I warrants to purchase up to 15,038,702 shares at $0.325/share, exercisable for 5 years after shareholder approval.
- Placement agent (Ladenburg Thalmann) received 451,162 warrants at $0.40625/share (125% of offering price).
- Total potential dilution: 7,519,351 shares + 15,038,702 warrant shares + 451,162 agent warrants = ~23M new shares, dwarfing the current market cap of ~$2M.
- Shareholder meeting required by July 21, 2026 to approve warrant exercise; warrants are non-exercisable until approval.
- This offering follows a 424B5 filed May 19 suspending an ATM facility, and a 424B5 filed May 21 for the same offering.
- Company has a $2M market cap and is a pre-revenue clinical-stage biotech with ongoing financial distress.
Financial Impact
Gross proceeds of ~$2.44M at a 21% discount; potential dilution of up to ~23M shares vs. ~$2M market cap, representing massive overhang.
Risk Factors
- Massive dilution from 7.5M shares and up to 15.5M additional warrant shares could overwhelm the micro-cap float.
- Shareholder approval for warrants may fail, but the company has committed to repeated votes every 90 days until approval.
- Company has a history of repeated dilutive financings; cash runway remains uncertain.
- Pre-revenue clinical-stage biotech with no approved products and ongoing losses.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024760 |
| Exhibit: ex4-1.htm | 0001493152-26-024760 |
| Exhibit: ex4-2.htm | 0001493152-26-024760 |
| Exhibit: ex10-2.htm | 0001493152-26-024760 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers